Back to Agenda
Session 3B: HEOR: Value of Health Economics and Outcomes Research and Knowledge Transfer
Session Chair(s)
Darryl L'Heureux, PhD, MPharm, MSc
Director, Clinical Science, Medical Writing, and Publications, Ambrx, Inc, United States
Recent changes to the reimbursement landscape have elevated the importance of health economics and outcomes research (HEOR) within the pharmaceutical industry. Ensuring that a new medicine or device provides the health care system with “value” is the focus of the science of HEOR. As a result of new demands from payers and Population-Based Decision Makers (PBDMs), market access considerations are now seen as integral to drug development from its earliest stages and throughout its life cycle. During development, companies collect important information to help define the clinical value of a new medicine - from clinical metrics to patient reported outcomes and preference studies. Compiling this information into a cogent dossier to inform a formulary decision or health technology assessment is a specialized form of communication that benefits from an understanding of clinical science, health economics, and systems policies. This session will introduce key concepts in HEOR, discuss current regulatory landscape, and provide insights and tools to prepare value dossiers for submission to US health plans and to HTA-based national health programs. Best practices in presenting HEOR communications and preparing pharmacoeconomic publications will be discussed.
Learning Objective : At the conclusion of this session, participants should be able to:- Recognize the evolution of HEOR in drug development and changing roles
- Identify value-based components of HEOR
- Compare different models for economic evaluations and cost-effectiveness
- Describe the key elements of a value dossier and review how value decisions are approached by formularies and health technology assessors
Speaker(s)
John Brokars
Health Outcomes Scientist , Bristol-Myers Squibb , United States
Real-World Data and HEOR Value Messages
Stacie Hudgens, MA
Managing Partner, Clinical Outcomes Solutions, United States
Evaluation of Patient Outcomes Communicating Safety and Treatment Benefit
Chad Green, PharmD, MBA
Director, Medical Communications , Clinical Outcomes Solutions, United States
Communication of HEOR Information with Payors and Formulary Committees
Panel Discussion
, All Session Speakers, United States
Have an account?